

OMTM, Volume 10

Supplemental Information

A Direct Comparison of IV and ICV Delivery


Methods for Gene Replacement Therapy

in a Mouse Model of SMARD1




Monir Shababi, Eric Villalón, Kevin A. Kaifer, Vince DeMarco, and Christian L. Lorson

A

Collagen III/I in arterial wall


**B**

CTGF in cardiomyocytes

**C**TGF β 1 in cardiomyocytes**D**TGF β 1 in arterial wall


A

Left Atrial Diameter




B

Aorta Diameter




C

Myocardial performance index



D

Heart Rate




Heart Extract (PND 14)

HEK293/
IGHMBP2

Non-Transgenic

Transgenic

110 →
KDa



Anti-IGHMBP2

← 55-60 KDa



Anti-Tubulin

Control

WT

HET

HET

HET

nmd

Figure S1. Expression levels of ECM proteins and growth factors in Cardiomyocytes and arteries of *nmd* heart. (A) Ratio of collagen III/I in arteries (one-way ANOVA unaffected control vs. *nmd*, IV, and ICV treated, $P < 0.05$); (B) Expression of CTGF in cardiomyocytes (one-way ANOVA IV-treated vs. *nmd*, $P < 0.01$; ICV-treated vs. *nmd*, $P < 0.05$) (C, D) expression of TGF β in cardiomyocytes (C) and arteries (D). The levels of TGF β are not significantly different between the cohorts.

Figure S2. Functional parameters of *nmd* heart. (A) Left atrial diameter; (B) Aorta diameter; (C) Myocardial performance index (one-way ANOVA controls vs. *nmd*, $P < 0.05$); (D) Heart rate. BPM (beat per minute).

Figure S3. Expression level of IGHMBP2 in cardiac rescue transgenic *nmd*. Western blot with the heart extracts of non-transgenic and cardiac rescue transgenic *nmd* detects a low expression of IGHMBP2 in transgenic heart. HEK 293 cells transfected with IGHMBP2 construct was used as size control and anti-tubulin was used as loading control.